The article “The Effect of Antihypertensive Therapy on Skeletal Muscle Mass and Bone Mineral Density in Patients With End-Stage Kidney Disease” by Hashimoto et al., 2024, has piqued our interest.1 The authors' endeavors to address the risks of osteoporosis and sarcopenia in patients with end-stage kidney disease are commendable. The article indicates that the use of beta blockers is linked to an elevated risk of sarcopenia, whereas renin–angiotensin system inhibitors seem to mitigate this risk. Additionally, the authors suggest that calcium channel blockers are responsible for a decrease in bone mineral density.